achillion pharmaceuticals (ACHN) Key Developments
Achillion Pharmaceuticals Reports Positive Interim Results from Odalasvir Study
Sep 17 15
Achillion Pharmaceuticals, Inc. announced additional interim results from a Phase 2 study evaluating odalasvir, also known as ACH-3102, a NS5A inhibitor, in combination with sofosbuvir, without ribavirin, for either six or eight weeks of treatment in patients with treatment-na¯ve genotype 1 chronic hepatitis C virus infection. The primary objective of the study was determination of sustained viral response 12 weeks, or SVR12, after the completion of therapy. The company said, of the patients treated for six weeks in this cross-over cohort, 100% remained HCV RNA undetectable twelve weeks after completing therapy. The company said Odalasvir and sofosbuvir were well tolerated in the Phase 2, open-label, randomized, partial-crossover study with no significant adverse events, ECG findings, or lab abnormalities observed during treatment.
Achillion Pharmaceuticals, Inc. Presents at Morgan Stanley Global Healthcare Conference - New York, Sep-17-2015 10:35 AM
Aug 14 15
Achillion Pharmaceuticals, Inc. Presents at Morgan Stanley Global Healthcare Conference - New York, Sep-17-2015 10:35 AM. Venue: The Grand Hyatt New York, 109 East 42nd Street, New York, New York, United States. Speakers: Milind S. Deshpande, Chief Executive Officer, President and Director.
Achillion Pharmaceuticals, Inc. Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Earnings Guidance for the Full Year of 2015
Aug 10 15
Achillion Pharmaceuticals, Inc. reported unaudited earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported a net loss of $29.0 million or $0.25 per share, compared with a net loss of $15.7 million or $0.16 per share for the second quarter of 2014. Revenue was $711,000. Loss from operations was $29,188,000 compared to $15,766,000 a year ago.
For the six months ended June 30, 2015, the company reported a net loss of $48.2 million, compared to a net loss of $31.7 million in the same period in 2014. The company recognized $711,000 in revenue during the six months ended June 30, 2015 representing a portion of the premium paid by JJDC associated with its equity purchase of the company’s common stock. Revenues were $711,000. Loss from operations was $48,587,000 compared to $32,001,000 a year ago. Basic and diluted net loss per share was $0.42 compared to $0.33 a year ago.
The Company expects total annual revenue to be $66 million. The company expects that research and development expenses during 2015 will be approximately $60 million to $65 million, compared to previously provided guidance of $85 million to $95 million, and that general and administrative expenses will add $20 million to $25 million of expense with an annual net loss anticipated of $18 million to $20 million. Net cash used in operating activities in 2015 will be approximately $65 to $70 million, based on current operating plans, anticipated timelines and the estimated cost of clinical trials and product development programs, as compared to previous guidance of $100 million to $110 million. The net loss per share is anticipated to be approximately $0.15 per share.
Achillion Pharmaceuticals, Inc. to Report Q2, 2015 Results on Aug 10, 2015
Aug 5 15
Achillion Pharmaceuticals, Inc. announced that they will report Q2, 2015 results on Aug 10, 2015
Achillion Pharmaceuticals, Inc. Presents at Baird 2015 Healthcare Conference, Sep-09-2015 12:15 PM
Jul 22 15
Achillion Pharmaceuticals, Inc. Presents at Baird 2015 Healthcare Conference, Sep-09-2015 12:15 PM. Venue: The New York Palace, 455 Madison Avenue, New York, New York, United States. Speakers: Milind S. Deshpande, Chief Executive Officer, President and Director.